ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,473.17
-0.25%
Dow Jones
39,134.76
0.77%
US Dollar vs MXN
18.3268
-0.15%
Brent Oil
84.975
-0.04%
Bitcoin
64,538.73
-0.43%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NYSE
  6. Taro Pharmaceutical Industries Ltd (TARO)

  7. Taro Pharmaceutical Industries Ltd (TARO) Noticias

TARO

Taro Pharmaceutical Indu... (TARO)

Taro Pharmaceutical Industries Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NYSE:TARO
FechaHoraFuenteTítuloSímboloCompañía
23/05/202407:10PR Newswire (US)Taro Shareholders Approve Merger with Sun PharmaNYSE:TAROTaro Pharmaceutical Industries Ltd
23/05/202407:01Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NYSE:TAROTaro Pharmaceutical Industries Ltd
23/05/202406:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:TAROTaro Pharmaceutical Industries Ltd
20/05/202416:00Business WireTaro Provides Results for Year Ended March 31, 2024NYSE:TAROTaro Pharmaceutical Industries Ltd
15/05/202408:00Business WireTaro to Release Full Year Results on May 20, 2024NYSE:TAROTaro Pharmaceutical Industries Ltd
08/05/202408:07Business WireLeading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma MergerNYSE:TAROTaro Pharmaceutical Industries Ltd
15/04/202407:00Business WireTaro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.NYSE:TAROTaro Pharmaceutical Industries Ltd
15/02/202407:36Edgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNYSE:TAROTaro Pharmaceutical Industries Ltd
30/01/202412:18PR Newswire (US)Kuehn Law Encourages PGTI, TAST, TARO, and ANSS Investors to Contact Law FirmNYSE:TAROTaro Pharmaceutical Industries Ltd
30/01/202406:00PR Newswire (US)Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for TaroNYSE:TAROTaro Pharmaceutical Industries Ltd
25/01/202416:06Business WireTaro Provides Results for December 31, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
19/01/202415:15Business WireTaro to Release Third Quarter Results on January 25, 2024NYSE:TAROTaro Pharmaceutical Industries Ltd
17/01/202415:35Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NYSE:TAROTaro Pharmaceutical Industries Ltd
17/01/202415:30PR Newswire (US)Taro Announces Merger Agreement with Sun PharmaNYSE:TAROTaro Pharmaceutical Industries Ltd
26/10/202316:00Business WireTaro Provides Results for September 30, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
19/10/202315:30Business WireTaro to Release Second Quarter Results on October 26, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
26/07/202319:36Business WireTaro Provides Results for the Quarter Ended June 30, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
19/07/202315:00Business WireTaro to Release First Quarter Results on July 26, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
19/07/202306:00PR Newswire (US)Krensavage Asset Management Opposes Sun's Lowball Bid for TaroNYSE:TAROTaro Pharmaceutical Industries Ltd
30/06/202308:00Business WireTaro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
29/06/202315:32Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NYSE:TAROTaro Pharmaceutical Industries Ltd
28/06/202316:01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NYSE:TAROTaro Pharmaceutical Industries Ltd
26/05/202316:03Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NYSE:TAROTaro Pharmaceutical Industries Ltd
23/05/202318:00Business WireTaro Provides Results for Year Ended March 31, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
18/05/202315:46Business WireTaro to Release Full Year Results on May 23, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
24/01/202316:43Business WireTaro Provides Results for December 31, 2022NYSE:TAROTaro Pharmaceutical Industries Ltd
19/01/202316:02Business WireTaro to Release Third Quarter Results on January 24, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
27/10/202217:39Business WireTaro Provides Results for September 30, 2022NYSE:TAROTaro Pharmaceutical Industries Ltd
24/10/202211:37Business WireTaro to Release Second Quarter Results on October 27, 2022NYSE:TAROTaro Pharmaceutical Industries Ltd
15/08/202205:35TipRanksH.C. Wainwright Keeps Their Buy Rating on Taro Pharmaceutical (TARO)NYSE:TAROTaro Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TARO

Su Consulta Reciente

TSXV
RSLV
Reyna Silver
LSE
YJ54
Citi Fun 25
BIT
P1TMJ7
BNP Paribas Issuance
BIT
P1T7V1
NLBNPIT1T7V1 20240621 1900
NASDAQ
RAMIX
Ramirez Core Bond Fund I...
LSE
0A4S
Sunrun
BIT
P1NAF3
BNP Paribas Issuance
NASDAQ
AAZXQXX
Torontodominion Bank Iss...
BIT
NSCIT0549781
Davis & Morgan
LSE
76DN
Wells Fargo 49
NASDAQ
FTMLX
Franklin Moderate Alloca...
BIT
P1PW15
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados